人 GZMH 抗体对
01AB03452
Granzyme H (GZMH) is a chymotrypsin-like serine protease constitutively expressed in natural killer cells, serving as a critical component of the innate immune response against tumors and virus-infected cells. It induces target cell death by directly cleaving essential pathogen substrates and host proteins. Structurally, GZMH possesses a unique S1 pocket that prefers bulky aromatic residues at the P1 position and an RKR motif that specifies acidic residues at the P3' and P4' sites. A key mechanism of its antiviral activity involves the cleavage of adenovirus DNA-binding protein, which impairs viral DNA replication, and the 100K assembly protein, which relieves the inhibition of granzyme B to enhance overall cytotoxicity. Clinically, GZMH expression has demonstrated prognostic value in patients with head and neck squamous cell carcinoma, reflecting its role in tumor surveillance and the immune microenvironment.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- GZMH
- 基因别名
- CGL2; CTSGL2
- 蛋白别名
- granzyme H; GZMH
- UniProt
- P20718
- 物种
- Human
产品详情
- 靶点名称
- GZMH
- 蛋白名称
- granzyme H
- 蛋白别名
- Granzyme H; CCP-X; Cathepsin G-like 2; CTSGL2; Cytotoxic T-lymphocyte proteinase; Cytotoxic serine protease C; CSP-C
- 靶点基因名
- GZMH
- 基因别名
- CGL2; CTSGL2
- UniProt
- P20718
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Granzyme H (GZMH) is a chymotrypsin-like serine protease constitutively expressed in natural killer cells, serving as a critical component of the innate immune response against tumors and virus-infected cells. It induces target cell death by directly cleaving essential pathogen substrates and host proteins. Structurally, GZMH possesses a unique S1 pocket that prefers bulky aromatic residues at the P1 position and an RKR motif that specifies acidic residues at the P3' and P4' sites. A key mechanism of its antiviral activity involves the cleavage of adenovirus DNA-binding protein, which impairs viral DNA replication, and the 100K assembly protein, which relieves the inhibition of granzyme B to enhance overall cytotoxicity. Clinically, GZMH expression has demonstrated prognostic value in patients with head and neck squamous cell carcinoma, reflecting its role in tumor surveillance and the immune microenvironment.